Fig. 5.

BRD4 inhibition has antitumor effects in PDX xenografts derived from MYCN-high and c-MYC-high primary ovarian cancer strains. (A–C) JQ1 antitumor activity was evaluated in three luciferase-producing ovarian PDX models. Mice bearing xenografts derived from primary DF14 (MYCN-high) (A), DF86 (c-MYC-high) (B), or the low N and c-MYC DF181 (MYC-low) (C) were treated with vehicle (−) or JQ1 (+JQ1) (50 mg/kg once a day, intraperitoneally) for the indicated times starting on day 7 after implantation. Tumor growth was measured by weekly bioluminescence (BLI). Statistical significance of the results was evaluated using a two-way ANOVA test. Error bars represent standard deviations of measurements obtained for each group (n = 10).